# Jack Hoppin

> Jack Hoppin is the co-founder, chairman, and CEO of Ratio Therapeutics, a Boston-based biotech developing targeted radiopharmaceuticals for cancer. A mathematician by training with a PhD in applied mathematics, he previously co-founded the molecular imaging company Invicro and led Konica Minolta Precision Medicine. At Ratio he pairs with scientific co-founder John Babich to build fit-for-purpose radioligand therapies on the company's Trillium pharmacokinetic-modulation and Macropa chelation platforms, backed by investors including Bristol Myers Squibb and a partnership with Novartis.

- **Role:** Co-Founder, Chairman & CEO at Ratio Therapeutics
- **Organizations:** Ratio Therapeutics, Invicro, Konica Minolta Precision Medicine, Emit Imaging, Bioscan, Inc., Bioasis Technologies (Scientific Advisory Board)
- **Nationality:** American
- **Education:** BA, Mathematics, College of the Holy Cross, PhD, Applied Mathematics, University of Arizona, Alexander von Humboldt Post-Doctoral Fellow, Research Center Juelich
- **Known for:** Co-founded and scaled Invicro into a leading molecular imaging CRO, sold to Konica Minolta in 2017, Co-founded Ratio Therapeutics and built proprietary Trillium and Macropa technology platforms, Secured $50M Series B financing in 2024, bringing total raised to over $90M

## Career timeline

- **2008** — Co-founded Invicro, LLC, a molecular imaging and translational drug discovery company; served as Managing Partner
- **2017** — Sold majority of Invicro to Konica Minolta
- **2020** — Became President of Konica Minolta Precision Medicine
- **2021** — Co-founded Ratio Therapeutics and became CEO (October 2021)
- **2023** — Signed radiopharmaceutical partnership with Novartis (up to $745M in biobucks)
- **2024** — Closed $50M Series B financing with Bristol Myers Squibb, Schusterman, Duquesne and others
- **2025** — Announced new radiopharmaceutical manufacturing facility in Utah

## Achievements

- Co-founded and scaled Invicro into a leading molecular imaging CRO, sold to Konica Minolta in 2017
- Co-founded Ratio Therapeutics and built proprietary Trillium and Macropa technology platforms
- Secured $50M Series B financing in 2024, bringing total raised to over $90M
- Struck a radiopharmaceutical partnership with Novartis valued at up to $745M in milestones
- Attracted Bristol Myers Squibb as a strategic investor
- Advanced a FAP-targeted radiopharmaceutical toward clinical trials in soft tissue sarcoma

## Latest updates

- **2025-05** — Ratio Therapeutics announced plans to establish a new radiopharmaceutical manufacturing facility in Utah
- **2024-01** — Closed $50M Series B financing to advance targeted radiotherapies, with participation from Bristol Myers Squibb
- **2023-12** — Signed radiopharmaceutical collaboration with Novartis worth up to $745M in potential milestones

## Links

- Website: https://ratiotx.com
- LinkedIn: http://www.linkedin.com/in/jack-hoppin-a1b9007
- Twitter/X: https://twitter.com/Ratio_Tx

---

Profile page: https://yespress.io/jack-hoppin
Published by YesPress — https://yespress.io
Last updated: 2026-07-16